Last reviewed · How we verify
Atazanavir / Ritonavir + Tenofovir / Emtricitabine
Atazanavir / Ritonavir + Tenofovir / Emtricitabine is a Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) Small molecule drug developed by Juan A. Arnaiz. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in combination antiretroviral therapy.
This combination inhibits HIV protease and reverse transcriptase to suppress viral replication.
This combination inhibits HIV protease and reverse transcriptase to suppress viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults, HIV-1 infection in combination antiretroviral therapy.
At a glance
| Generic name | Atazanavir / Ritonavir + Tenofovir / Emtricitabine |
|---|---|
| Sponsor | Juan A. Arnaiz |
| Drug class | Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) |
| Target | HIV protease, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Atazanavir and ritonavir are protease inhibitors that block HIV protease, preventing maturation of infectious viral particles. Tenofovir and emtricitabine are nucleoside/nucleotide reverse transcriptase inhibitors that block the enzyme responsible for converting HIV RNA into DNA, preventing viral integration into host cells. Together, they provide dual-class antiretroviral activity against HIV-1.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
- HIV-1 infection in combination antiretroviral therapy
Common side effects
- Hyperbilirubinemia
- Nausea
- Diarrhea
- Headache
- Rash
- Renal impairment (tenofovir-related)
- Bone density loss (tenofovir-related)
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV (PHASE4)
- Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia (NA)
- Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses (PHASE2)
- A Study to Determine Safety and Efficacy of Dolutegravir/Abacavir/Lamivudine (DTG/ABC/3TC) in Human Immunodeficiency Virus (HIV)-1 Infected Antiretroviral Therapy (ART) Naïve Women (ARIA) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atazanavir / Ritonavir + Tenofovir / Emtricitabine CI brief — competitive landscape report
- Atazanavir / Ritonavir + Tenofovir / Emtricitabine updates RSS · CI watch RSS
- Juan A. Arnaiz portfolio CI
Frequently asked questions about Atazanavir / Ritonavir + Tenofovir / Emtricitabine
What is Atazanavir / Ritonavir + Tenofovir / Emtricitabine?
How does Atazanavir / Ritonavir + Tenofovir / Emtricitabine work?
What is Atazanavir / Ritonavir + Tenofovir / Emtricitabine used for?
Who makes Atazanavir / Ritonavir + Tenofovir / Emtricitabine?
What drug class is Atazanavir / Ritonavir + Tenofovir / Emtricitabine in?
What development phase is Atazanavir / Ritonavir + Tenofovir / Emtricitabine in?
What are the side effects of Atazanavir / Ritonavir + Tenofovir / Emtricitabine?
What does Atazanavir / Ritonavir + Tenofovir / Emtricitabine target?
Related
- Drug class: All Antiretroviral combination (protease inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV protease, HIV reverse transcriptase
- Manufacturer: Juan A. Arnaiz — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
- Indication: Drugs for HIV-1 infection in combination antiretroviral therapy
- Compare: Atazanavir / Ritonavir + Tenofovir / Emtricitabine vs similar drugs
- Pricing: Atazanavir / Ritonavir + Tenofovir / Emtricitabine cost, discount & access